Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 1.4 USD 2.94% Market Closed
Market Cap: 314.6m USD

Wall Street
Price Targets

ALLO Price Targets Summary
Allogene Therapeutics Inc

Wall Street analysts forecast ALLO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALLO is 7.71 USD with a low forecast of 1.62 USD and a high forecast of 14.7 USD.

Lowest
Price Target
1.62 USD
15% Upside
Average
Price Target
7.71 USD
451% Upside
Highest
Price Target
14.7 USD
950% Upside
Allogene Therapeutics Inc Competitors:
Price Targets
2696
Shanghai Henlius Biotech Inc
69% Upside
TECX
AVROBIO Inc
274% Upside
301207
Hualan Biological Bacterin Inc
2% Upside
NVAX
Novavax Inc
88% Upside
ALEC
Alector Inc
44% Upside
002252
Shanghai RAAS Blood Products Co Ltd
11% Upside
ADMA
ADMA Biologics Inc
34% Upside
MIRM
Mirum Pharmaceuticals Inc
29% Upside

Revenue
Forecast

Revenue Estimate
Allogene Therapeutics Inc

The compound annual growth rate of Allogene Therapeutics Inc's revenue for the next 4 years is 829%.

N/A
Past Growth
829%
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Allogene Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
Allogene Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-43%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALLO's stock price target?
Price Target
7.71 USD

According to Wall Street analysts, the average 1-year price target for ALLO is 7.71 USD with a low forecast of 1.62 USD and a high forecast of 14.7 USD.

What is Allogene Therapeutics Inc's Revenue forecast?
Projected CAGR
829%

The compound annual growth rate of Allogene Therapeutics Inc's revenue for the next 4 years is 829%.

Back to Top